mRNA COVID-19 Vaccine Transition

Commissioner Lambrew letterhead

To: Maine Immunization Program Providers

From: Maine Immunization Program

Subject: mRNA COVID-19 Vaccine Transition

Date: April 13, 2023

In response to a call with the federal CDC yesterday, April 12, 2023, the Maine Immunization Program has discontinued ordering of all monovalent mRNA COVID-19 vaccinations within Immpact. With the exception of Novavax and Johnson & Johnson/Janssen, as they do not currently have authorized bivalent vaccines, the monovalent, non-mRNA vaccines authorizations and vaccination schedules will remain.

This decision is based on the recommendation from ACIP to simplify COVID-19 vaccination. If authorized by FDA, CDC anticipates that a recommendation for bivalent mRNA COVID-19 vaccine to be used for vaccination of all age groups to be implemented as early as next week (April 17th).

We are notifying you with this preliminary information for planning purposes only. A new schedule and further guidance is anticipated and will be provided as soon as it is published.

Should you have any questions, please contact us at (207) 287-3746 or email: ImmunizeME.DHHS@maine.gov.